Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 4, 2019

View Archived Issues

Prion protein with gain of function found

Impaired ATM function linked to worse rheumatoid arthritis

MAC-545496, a potent inhibitor that attenuates virulence and reverses antibiotic resistance in MRSA

AXS-12 achieves primary endpoint in CONCERT phase II study in narcolepsy

Biogen reports phase II data from LILAC study of BIIB-059

Early data from first patient in phase Ib/II study of leronlimab in CCR5-poisitive mTNBC

Positive interim data reported from ongoing phase IIa combination portion of CANFOUR study

Positive topline data from part 1 of adaptive phase III RENEW study of reproxalap

Preliminary phase II results for PTG-300 in transfusion-dependent beta-thalassemia

StemoniX and Atomwise create joint venture that will initially target Rett syndrome

P. falciparum-induced malaria model created in immunocompromised juvenile mice

89Zr-DFO-MSTP-2109A shows promise as companion diagnostic in patients with mCRPC

Results form phase II study of galunisertib in MDS

Study shows how individual brain cell types contribute to AD

Vivace Therapeutics patents transcriptional coactivator YAP1/TEAD interaction inhibitors

FDA accepts IND for phase I trial of SKL-24741 for epilepsy

Sichuan Kelun-Biotech Biopharmaceutical presents ARG1-targeting PROTACs

New macrophage metalloelastase inhibitors discovered at Foresee Pharmaceuticals

Nuvation Bio discovers PARP inhibitors

Abide Therapeutics identifies new monoglyceride lipase inhibitors

Phase II trial of CNSA-001 in PKU meets primary and secondary endpoints

Xenikos initiates phase III study of T-Guard for steroid-refractory GvHD

Healthy volunteer safety data reported from phase IIb study of EB-01 in allergic contact dermatitis

Calmodulinopathy model used to study development of arrythmias

Tiziana begins phase I trial of oral foralumab in healthy volunteers

Popular Stories

Today's news in brief
BioWorld
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...